In patients with gestational diabetes mellitus, metformin is an effective alternative to insulin, according to the findings of a recent single-center randomized controlled study.
Patients with stage IVB, recurrent, or persistent cervical cancer that was not cured with standard treatment who were given the angiogenesis inhibitor bevacizumab lived 3.7 months longer than patients who did not receive the drug, but adverse events increased.
There is no evidence that plastic adhesive surgical drapes reduce surgical site infection rates, and some evidence that these drapes may increase infection rates, according to a third update of an intervention review and analysis conducted by the Cochrane Wounds Group.
In clinical trials, 12 weeks of desvenlafaxine effectively treated moderate to severe hot flashes in postmenopausal women, and the benefit remained after 1 year of maintenance treatment.
Immediate start of hormonal contraception may reduce unintended pregnancies and increase method continuation, but the evidence is limited, according to the findings of an intervention review conducted by the Cochrane Fertility Regulation Group.
The current genitourinary fistula classification systems have poor to fair prognostic value, as does an empirically derived scoring system that predicts fistula closure 3 months after surgery, according to the findings of a new prospective cohort study.
The use of APTIMA human papillomavirus (AHPV) assay for the detection of high-risk human papillomavirus E6/E7 oncogenic messenger RNA is an effective triage method for colposcopy referral in women with atypical squamous cells of undetermined significance cytology (ASC-US).
Women who have migraine with aura, especially those who take combined hormonal contraceptives (CHCs) have an increased risk for cardiovascular or thrombotic events.
On January 18, 2013, the FDA announced its approval of onabotulinumtoxinA (Botox) for the treatment of overactive bladder in adults who cannot use or who do not respond adequately to anticholinergic medications.
An independent panel convened by the NIH has concluded that the name “polycystic ovary syndrome (PCOS)” causes confusion and is a barrier to progress in the realms of both research and effective patient care.